Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Epizon Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed between 2 distinct examiners, with each examiner handling one of the pending matters. The portfolio also spans 2 distinct art units, indicating that even with a small number of active cases, the company is engaging with different specialized groups within the patent office. This distribution suggests that the 2 pending office actions are likely focused on different technical aspects of biotechnology.
The busiest examiner, DONOHUE, SEAN R, is responsible for 1 pending office action. With the 2 pending office actions split across 2 distinct examiners and 2 distinct art units, there is no overlap in the current prosecution of these matters. This requires the applicant to address the unique requirements of two different administrative environments. For practitioners, the lack of concentration means that the outcome of one action is unlikely to influence the other, as they are being reviewed by different individuals in different units. The focus remains on the 2 distinct examiners and their respective actions within the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, WILLIAM A | 1 | 48.9% | +38.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19272770 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | CRAIGO, WILLIAM A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19272770 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | CRAIGO, WILLIAM A | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19272770 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | CRAIGO, WILLIAM A | 1615 | §103§112Other | Non-Final OA | — | Pending | Jul 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpizon Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William A Craigo has the most, with 1 of Epizon Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
